Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphatidic acid (PA) is a fundamental phospholipid that serves both as a central intermediate in lipid biosynthesis and as a critical bioactive signaling molecule (PubChem CID 452). It is characterized by a glycerol backbone, two fatty acid chains, and a phosphate group, giving it a unique cone-shaped geometry that promotes membrane curvature and fusion (PubMed: 12648486). In signaling, PA acts as a second messenger that recruits and activates various effector proteins, most notably the mechanistic target of rapamycin (mTOR), which is essential for cell growth and protein synthesis (PubMed: 15544351). Dysregulation of PA levels is implicated in several pathologies, including cancer, where overactive phospholipase D (PLD) leads to elevated PA and sustained growth signaling (PubMed: 21746959). Consequently, PA and the enzymes responsible for its production are significant areas of interest for therapeutic intervention, particularly in oncology and regenerative medicine. Additionally, PA is utilized as a dietary supplement to enhance muscle mass by stimulating the mTOR pathway in response to resistance exercise (PubMed: 23075554). Beyond its role in growth, PA is involved in vesicular trafficking and the regulation of various ion channels and kinases (PubMed: 11062244). Its ability to act as a pH sensor also allows it to link cellular metabolism with signaling pathways (PubMed: 20972427).
Phosphatidic acid acts as a lipid second messenger that recruits and allosterically activates signaling proteins such as mTOR and Raf-1 to the membrane (PubMed: 15544351). It also modulates membrane physical properties, specifically inducing negative curvature to facilitate vesicle fusion and fission (PubMed: 12648486). Pharmacological modulation typically involves inhibiting enzymes like phospholipase D (PLD) to decrease PA levels in cancer or using exogenous PA to stimulate muscle protein synthesis (PubMed: 23075554).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphatidic acid (PA) (PA).